References
- de Boer RA, Lok DJA, Jaarsma T, et al. (2011). Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43:60–8
- Dutta P, Courties G, Wei Y, et al. (2012). Myocardial infarction accelerates atherosclerosis. Nature 487:325–9
- Falcone C, Lucibello S, Mazzucchelli I, et al. (2011). Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol 24:905–13
- Felker GM, Fiuzat M, Shaw LK, et al. (2012). Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION Study. Circ Heart Fail 5:72–8
- Galkina E, Ley K. (2009). Immune and inflammatory mechanisms of atherosclerosis. Ann Rev Immunol 27:165–97
- Gierlotka M, Gąsior M, Wilczek K, et al. (2012). Temporal trends in the treatment and outcomes of patients with non-ST-segment elevation myocardial infarction in Poland from 2004--2010 (from the Polish Registry of Acute Coronary Syndromes). Am J Cardiol 109:779–86
- Hansson GK. (2005). Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–95
- Hansson GK, Robertson AL, Söderberg-Nauclér C. (2006). Inflammation and atherosclerosis. Ann Rev Pathol 1:297–329
- Henderson NC, Mackinnon AC, Farnworth SL, et al. (2006). Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 103:5060–5
- Henderson NC, Mackinnon AC, Farnworth SL, et al. (2008). Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172:288–98
- Katsuda S, Kaji T. (2003). Atherosclerosis and extracellular matrix. J Atheroscler Thromb 10:267–74
- Lan T-H, Huang X-Q, Tan H-T. (2013). Vascular fibrosis in atherosclerosis. Cardiovasc Pathol 22:401--7
- Libby P, Ridker PM, Hansson GK. (2011). Progress and challenges in translating the biology of atherosclerosis. Nature 473:317–25
- Lin YH, Lin LY, Wu YW, et al. (2009). The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409:96–9
- Lok DJA, van der Meer P, Pieta W, et al. (2010). Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 99:323–8
- Lopez-Andres N, Rossignol P, Iraqi W, et al. (2012). Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (cardiac resynchronization in heart failure) trial. Eur J Heart Fail 14:74–81
- Milonas C, Jernberg T, Lindbäck J, et al. (2010). Effect of Angiotensin-converting enzyme inhibition on one-year mortality and frequency of repeat acute myocardial infarction in patients with acute myocardial infarction. Am J Cardiol 105:1229–34
- Moore KJ, Tabas I. (2011). Macrophages in the pathogenesis of atherosclerosis. Cell 145:341–55
- Shah RV, Chen-Tournoux AA, Picard MH, et al. (2010). Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 12:826–32
- Sharma UC, Pokharel S, van Brakel TJ, et al. (2004). Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121–8
- Świątkiewicz I, Magielski P, Woźnicki M, et al. (2012). Occurrence and predictors of left ventricular systolic dysfunction at hospital discharge and in long-term follow-up after acute myocardial infarction treated with primary percutaneous coronary intervention. Kardiol Pol 4:329–40
- Szadkowska I, Pawlicki L, Kowalski J, et al. (2009). Left ventricular dysfunction and NT-proBNP levels in patients with one-vessel disease after first ST-elevation myocardial infarction treated with primary coronary angioplasty. Kardiol Pol 67:1201–6
- Wang KF, Huang PH, Chiang CH, et al. (2013). Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction. Coron Artery Dis 24:23–8
- Wright PA, Öhman MK, Hayasaki T, et al. (2010). Atherosclerosis and leukocyte-endothelial adhesive interactions are increased following acute myocardial infarction in apolipoprotein E deficient mice. Atherosclerosis 212:414–17
- Yang RY, Rabinovich GA, Liu FT. (2008). Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 13:e17–39